<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37885796</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Prevalence of Long-term Symptoms Varies When Using Different Post-COVID-19 Definitions in Positively and Negatively Tested Adults: The PRIME Post-COVID Study.</ArticleTitle><Pagination><StartPage>ofad471</StartPage><MedlinePgn>ofad471</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad471</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad471</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long-term symptoms after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (ie, post-coronavirus disease 2019 [COVID-19] condition or long COVID) constitute a substantial public health problem. Yet, the prevalence remains currently unclear as different case definitions are used, and negatively tested controls are lacking. We aimed to estimate post-COVID-19 condition prevalence using 6 definitions.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The Prevalence, Risk factors, and Impact Evaluation (PRIME) post-COVID-19 condition study is a population-based sample of COVID-19-tested adults. In 2021, 61 655 adults were invited to complete an online questionnaire, including 44 symptoms plus a severity score (0-10) per symptom. Prevalence was calculated in both positively and negatively tested adults, stratified by time since their COVID-19 test (3-5, 6-11, or &#x2265;12 months ago).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In positive individuals (n = 7405, 75.6%), the prevalence of long-term symptoms was between 26.9% and 64.1% using the 6 definitions, while in negative individuals (n = 2392, 24.4%), the prevalence varied between 11.4% and 32.5%. The prevalence of long-term symptoms potentially attributable to COVID-19 ranged from 17.9% to 26.3%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">There is a (substantial) variation in prevalence estimates when using different post-COVID-19 condition definitions, as is current practice; there is limited overlap between definitions, indicating that the essential post-COVID-19 condition criteria are still unclear. Including negatives is important to determine long-term symptoms attributable to COVID-19.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT05128695.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pagen</LastName><ForeName>Demi M E</ForeName><Initials>DME</Initials><Identifier Source="ORCID">0000-0003-1475-5474</Identifier><AffiliationInfo><Affiliation>Department of Sexual Health, Infectious Diseases, and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Medicine, Maastricht University, Faculty of Health, Medicine, and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Bilsen</LastName><ForeName>C&#xe9;line J A</ForeName><Initials>CJA</Initials><AffiliationInfo><Affiliation>Department of Sexual Health, Infectious Diseases, and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Medicine, Maastricht University, Faculty of Health, Medicine, and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkhues</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Knowledge &amp; Innovation, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Herck</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Research and Education, Ciro, Horn, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, School of Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine, and Life Sciences, Maastricht University Medical Centre+, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REVAL-Rehabilitation Research Center, BIOMED-Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konings</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Process &amp; Information Management, Communication &amp; Automation, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Heijer</LastName><ForeName>Casper D J</ForeName><Initials>CDJ</Initials><AffiliationInfo><Affiliation>Department of Sexual Health, Infectious Diseases, and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Medicine, Maastricht University, Faculty of Health, Medicine, and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ter Waarbeek</LastName><ForeName>Henri&#xeb;tte L G</ForeName><Initials>HLG</Initials><AffiliationInfo><Affiliation>Department of Sexual Health, Infectious Diseases, and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spruit</LastName><ForeName>Martijn A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Research and Education, Ciro, Horn, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, School of Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine, and Life Sciences, Maastricht University Medical Centre+, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoebe</LastName><ForeName>Christian J P A</ForeName><Initials>CJPA</Initials><AffiliationInfo><Affiliation>Department of Sexual Health, Infectious Diseases, and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Medicine, Maastricht University, Faculty of Health, Medicine, and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre+, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dukers-Muijrers</LastName><ForeName>Nicole H T M</ForeName><Initials>NHTM</Initials><AffiliationInfo><Affiliation>Department of Sexual Health, Infectious Diseases, and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Promotion, Faculty of Health, Medicine, and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05128695</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">definitions</Keyword><Keyword MajorTopicYN="N">long-term symptoms</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. All authors: no reported conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37885796</ArticleId><ArticleId IdType="pmc">PMC10599319</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad471</ArticleId><ArticleId IdType="pii">ofad471</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard . Available at: https://covid19.who.int/. Accessed 11 January 2023.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Network Open 2021; 4:e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaes AW, Go&#xeb;rtz YMJ, Van Herck M, et al. . Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members. ERJ Open Res 2021; 7:00141-2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012818</ArticleId><ArticleId IdType="pubmed">34041295</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope AA, Evering TH. Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Infect Dis Clin North America 2022; 36:379&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843334</ArticleId><ArticleId IdType="pubmed">35636906</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization (WHO) . A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 24 August 2022.</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence (NICE) . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021. Available at: https://www.nice.org.uk/guidance/ng188/chapter/Recommendations. 25 October 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA 2020; 324:2251&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaden T, Mutubuki EN, de Bruijn S, et al. . Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands. J Infect Dis 2023; 227:1059&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">36477364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SK, Olde Hartman TC, Rosmalen JG, Initiative LCR. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 2022; 400:452&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. . Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health-Eur 2021; 6:100122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun 2022; 13:1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Beridze G, Triolo F, Grande G, Fratiglioni L, Calder&#xf3;n-Larra&#xf1;aga A. COVID-19 collateral damage&#x2014;psychological burden and behavioural changes among older adults during the first outbreak in Stockholm, Sweden: a cross-sectional study. BMJ Open 2022; 12:e058422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743841</ArticleId><ArticleId IdType="pubmed">34996805</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiesa V, Antony G, Wismar M, Rechel B. COVID-19 pandemic: health impact of staying at home, social distancing and &#x2018;lockdown&#x2019; measures&#x2014;a systematic review of systematic reviews. J Public Health (Oxf) 2021; 43:e462&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083256</ArticleId><ArticleId IdType="pubmed">33855434</ArticleId></ArticleIdList></Reference><Reference><Citation>Colucci E, Nadeau S, Higgins J, et al. . COVID-19 lockdowns&#x2019; effects on the quality of life, perceived health and well-being of healthy elderly individuals: a longitudinal comparison of pre-lockdown and lockdown states of well-being. Arch Gerontol Geriatr 2022; 99:104606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645291</ArticleId><ArticleId IdType="pubmed">34896795</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med 2021; 27:1129&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaden T, Mutubuki EN, de Bruijn S, et al. . Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands. J Infect Dis 2023; 227:1059&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">36477364</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagen DME, van Bilsen CJA, Brinkhues S, et al. . Design and recruitment of a large-scale cohort study on prevalence, risk factors and impact evaluation of post-COVID-19 condition and its wider long-term social, mental, and physical health impact: the PRIME post-COVID study. Front Public Health 2022; 10:1032955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9799054</ArticleId><ArticleId IdType="pubmed">36589958</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YM, Van Herck M, Delbressine JM, et al. . Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020; 6:00542-2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulley C, Tyagi V, Curnow E, et al. . Support after COVID-19 study: a mixed-methods cross-sectional study to develop recommendations for practice. BMJ Open 2022; 12:e056568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9437739</ArticleId><ArticleId IdType="pubmed">36038169</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Gualano MR, Rossi MF, et al. . Post-acute COVID-19 sequelae in a working population at one year follow-up: a wide range of impacts from an Italian sample. Int J Environ Res Public Health 2022; 19:11093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9518581</ArticleId><ArticleId IdType="pubmed">36078808</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong A, Baumgart A, Evangelidis N, et al. . Core outcome measures for trials in people with coronavirus disease 2019: respiratory failure, multiorgan failure, shortness of breath, and recovery. Crit Care Med 2021; 49:503&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892260</ArticleId><ArticleId IdType="pubmed">33400475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. . Outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland study. Nat Commun 2022; 13:5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators; Wulf Hanson S, Abbafati C, Aerts JG, et al. . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Etymologia: Bonferroni correction. Emerg Infect Dis 2015; 21:289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313667</ArticleId><ArticleId IdType="pubmed">25786274</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Network Open 2021; 4:e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch V, Yelin D, Awwad M, et al. . Characteristics of long COVID among older adults: a cross-sectional study. Int J Infect Dis 2022; 125:287&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">36191820</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjam SS, Balhara YPS, Kumar P, et al. . A comprehensive assessment of self-reported post COVID-19 symptoms among beneficiaries of Hospital Employee Scheme at a Tertiary Healthcare Institution in Northern India. Int J Gen Med 2022; 15:7355&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9509009</ArticleId><ArticleId IdType="pubmed">36164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, et al. . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 2022; 13:1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022; 10:761&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>